Immunotherapy plus targeted therapy and chemo for AFP-high stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (an immunotherapy, a targeted therapy, and chemotherapy) as a first treatment for people with advanced stomach cancer that has high levels of AFP. It aims to see if this combination can shrink tumors and help people live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced stomach cancer that has not been treated before, and your blood or tumor has high AFP levels.
- You are healthy enough to do light daily activities (ECOG score 0 or 1).
- Your major organs (like liver, kidneys, blood cells) are working well enough based on blood tests.
- You can take pills by mouth.
- You are not pregnant, and you agree to use birth control during and for 4 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three treatments—an immunotherapy drug (sintilimab), a blood-vessel-blocking drug (bevacizumab), and chemotherapy—for advanced stomach cancer that cannot be surgically removed but has elevated AFP levels (a tumor marker). The goal is to shrink the tumor and potentially make it operable.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (apatinib) and a chemotherapy drug (irinotecan hydrochloride) for people with a rare type of advanced stomach cancer called AFP-producing gastric cancer. It is for patients whose cancer did not respond to previous immunotherapy combined with chemotherapy.
This trial tests a new combination of chemotherapy (XELOX) plus two immunotherapy/targeted drugs (Sintilimab and Lenvatinib) in people with advanced stomach cancer that produces a high level of a protein called AFP. It aims to see if this combination is safe and can shrink tumors when given as the first treatment.
This trial tests a combination of two targeted drugs (adebrelimab and apatinib) with standard chemotherapy (SOX regimen) before surgery for gastric cancer that cannot be removed right away. The goal is to shrink the tumor enough to make surgery possible.
This trial tests a new immunotherapy drug (serplulimab) combined with standard chemotherapy before surgery for patients with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new AFP Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.